IgG1 is pathogenic in Leishmania mexicana infection

Journal of Immunology

Volumn 185, Issue 11, 2010, Pages 6939-6946

  Chu, Niansheng ^a   Thomas, Bolaji N ^b   Patel, Supriya R ^a   Buxbaum, Laurence U ^a,c  

^a School of Veterinary Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TYPE; CELLULAR IMMUNITY; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, PROTOZOAN; BONE MARROW CELLS; CELLS, CULTURED; CHRONIC DISEASE; FEMALE; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOPHENOTYPING; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 78650667611     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002484     Document Type: Article

References (39)

1. World Health Organization. 2005. Leishmaniasis. Available at: http://www.who. int/leishmaniasis/en/. Accessed: October 14, 2010.
2. World Health Organization. 2002. World Health Report: Reducing Risks, Promoting Healthy Life. Available at: http://www.who.int/whr/2002/en/whr02-en. pdf. Accessed: October 14, 2010.
3. Bryceson, A. D., J. D. Chulay, M. Ho, M. Mugambii, J. B. Were, R. Muigai, C. Chunge, G. Gachihi, J. Meme, G. Anabwani, et al. 1985. Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans. R. Soc. Trop. Med. Hyg. 79:700-704.
4. Sundar, S., D. K. More, M. K. Singh, V. P. Singh, S. Sharma, A. Makharia, P. C. Kumar, and H. W. Murray. 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31:1104-1107.
5. Soto, J., J. Toledo, J. Vega, and J. Berman. 2005. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 72:421-422.
6. Austrian, R., R. M. Douglas, G. Schiffman, A. M. Coetzee, H. J. Koornhof, S. Hayden-Smith, and R. D. Reid. 1976. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 89:184-194.
7. Szmuness, W., C. E. Stevens, E. J. Harley, E. A. Zang, W. R. Oleszko, D. C. William, R. Sadovsky, J. M. Morrison, and A. Kellner. 1980. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 303:833-841.
8. Kane, M. M., and D. M. Mosser. 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166:1141-1147.
9. Buxbaum, L. U., and P. Scott. 2005. Interleukin 10-and Fcgamma receptordeficient mice resolve Leishmania mexicana lesions. Infect. Immun. 73:2101-2108.
10. Buxbaum, L. U., J. E. Uzonna, M. H. Goldschmidt, and P. Scott. 2002. Control of New World cutaneous leishmaniasis is IL-12 independent but STAT4 dependent. Eur. J. Immunol. 32:3206-3215.
11. Thomas, B. N., and L. U. Buxbaum. 2008. FcgammaRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions. Infect. Immun. 76:623-631.
12. Jung, S., K. Rajewsky, and A. Radbruch. 1993. Shutdown of class switch recombination by deletion of a switch region control element. Science 259:984-987.
13. Ioan-Facsinay, A., S. J. de Kimpe, S. M. Hellwig, P. L. van Lent, F. M. Hofhuis, H. H. van Ojik, C. Sedlik, S. A. da Silveira, J. Gerber, Y. F. de Jong, et al. 2002. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16:391-402.
14. Buxbaum, L. U., H. Denise, G. H. Coombs, J. Alexander, J. C. Mottram, and P. Scott. 2003. Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J. Immunol. 171:3711-3717.
15. Scharton-Kersten, T., L. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154:5320-5330.
16. Su, Z., and M. M. Stevenson. 2002. IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice. J. Immunol. 168:1348-1355.
17. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J. V. Ravetch. 2005. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23:41-51.
18. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310:1510-1512.
19. Sutterwala, F. S., G. J. Noel, P. Salgame, and D. M. Mosser. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J. Exp. Med. 188:217-222.
20. Hamaguchi, Y., Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder. 2006. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203:743-753.
21. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502-507.
22. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-290.
23. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716-3725.
24. Kurniawan, A., M. Yazdanbakhsh, R. van Ree, R. Aalberse, M. E. Selkirk, F. Partono, and R. M. Maizels. 1993. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J. Immunol. 150:3941-3950.
25. Ishizaka, A., Y. Sakiyama, M. Nakanishi, K. Tomizawa, E. Oshika, K. Kojima, Y. Taguchi, E. Kandil, and S. Matsumoto. 1990. The inductive effect of interleukin-4 on IgG4 and IgE synthesis in human peripheral blood lymphocytes. Clin. Exp. Immunol. 79:392-396.
26. Zelazowski, P., J. T. Collins, W. Dunnick, and C. M. Snapper. 1995. Antigen receptor cross-linking differentially regulates germ-line CH ribonucleic acid expression in murine B cells. J. Immunol. 154:1223-1231.
27. Snapper, C. M., and W. E. Paul. 1987. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944-947.
28. Shapiro, D. A., D. S. Threadgill, M. J. Copfer, D. A. Corey, T. L. McCool, L. L. McCormick, T. R. Magnuson, N. S. Greenspan, and J. R. Schreiber. 1998. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides undergo normal isotype switching after immunization with polysaccharide-protein conjugate vaccines. J. Immunol. 161:3393-3399.
29. McLay, J., E. Leonard, S. Petersen, D. Shapiro, N. S. Greenspan, and J. R. Schreiber. 2002. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J. Immunol. 168:3437-3443.
30. Han, Y., T. R. Kozel, M. X. Zhang, R. S. MacGill, M. C. Carroll, and J. E. Cutler. 2001. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol. 167:1550-1557.
31. Vieira, P., and K. Rajewsky. 1988. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 18:313-316.
32. Racine, R., and G. M. Winslow. 2009. IgM in microbial infections: taken for granted? Immunol. Lett. 125:79-85.
33. Langhorne, J., C. B. Evans, R. Asofsky, and D. W. Taylor. 1984. Immunoglobulin isotype distribution of malaria-specific antibodies produced during infection with Plasmodium chabaudi adami and Plasmodium yoelii. Cell. Immunol. 87:452-461.
34. Tardei, G., S. Ruta, V. Chitu, C. Rossi, T. F. Tsai, and C. Cernescu. 2000. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection. J. Clin. Microbiol. 38:2232-2239.
35. Roehrig, J. T., D. Nash, B. Maldin, A. Labowitz, D. A. Martin, R. S. Lanciotti, and G. L. Campbell. 2003. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg. Infect. Dis. 9:376-379.
36. Kapoor, H., K. Signs, P. Somsel, F. P. Downes, P. A. Clark, and J. P. Massey. 2004. Persistence of West Nile Virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. J. Clin. Virol. 31:289-291.
37. Million, M., F. Thuny, H. Richet, and D. Raoult. 2010. Long-term outcome of Q fever endocarditis: a 26-year personal survey. Lancet Infect. Dis. 10:527-535.
38. Deak, E., A. Jayakumar, K. W. Cho, K. Goldsmith-Pestana, B. Dondji, J. D. Lambris, and D. McMahon-Pratt. 2010. Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. Eur. J. Immunol. 40:1355-1368.
39. Witte, T. 2008. IgM antibodies against dsDNA in SLE. Clin. Rev. Allergy Immunol. 34:345-347.